1. Home /
    2. Altai Protocol Library /
  2. New Drug: Cabozantinib for differentiated thyroid cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Cabozantinib for differentiated thyroid cancer

New Drug: Cabozantinib for differentiated thyroid cancer
Study:
  • Double-blind, randomized Phase III trial (COSMIC-311)
  • RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib
  • Cabozantinib 60 mg daily vs. placebo
Efficacy:
  • ORR: 18% vs. 0%
  • Median PFS: 11.0 vs. 1.9 mos (HR: 0.22 [0.13-0.36])
  • OS numerically improved
Safety:
  • Any grade AEs: diarrhea (51% vs. 3%), hand-foot skin (46% vs. none), hypertension (28% vs. 5%), fatigue (27% vs. 8%), nausea (24% vs. 2%)

J Clin Oncol. 2021;39:suppl 6001

Brose MS, et al. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial

https://doi.org/10.1200/JCO.2021.39.15_suppl.6001

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More